Epstein-Barr Virus (EBV): Symptoms, Cancer Links & Prevention Research
What Is EBV?
Human herpesvirus 4 (HHV-4). Infects >90% of adults globally. Primary infection: often asymptomatic in children; infectious mononucleosis ("mono") in adolescents/young adults. Establishes lifelong latency in B cells.
Transmission
- Saliva (kissing, sharing drinks/utensils) — "kissing disease."
- Blood transfusion, organ transplant (rare).
- Sexual contact (possible).
EBV-Associated Malignancies
| Cancer | EBV Association | Key Features |
|---|---|---|
| Burkitt lymphoma | Endemic: ~95% EBV+; Sporadic: ~20% | Pediatric, jaw/abdomen; MYC translocation |
| Hodgkin lymphoma | Classical HL: ~40% EBV+ (mixed cellularity) | Reed-Sternberg cells; young adults/older |
| Nasopharyngeal carcinoma (NPC) | ~90-100% EBV+ (non-keratinizing) | Endemic in SE Asia, N. Africa; genetic susceptibility |
| Gastric carcinoma | ~9% EBV+ (lymphoepithelioma-like) | Distinct molecular subtype; better prognosis |
| Post-transplant lymphoproliferative disorder (PTLD) | Early lesions EBV+ | Immunosuppression-driven |
| Other | Extranodal NK/T-cell lymphoma, leiomyosarcoma (HIV) | Rare |
Pathogenesis: From Latency to Cancer
- Latency programs (0, I, II, III) express limited viral proteins (EBNAs, LMPs, EBERs).
- LMP1/2A mimic CD40/BCR signaling → proliferation, survival.
- EBNA1 disrupts p53, genome stability.
- Co-factors: Malaria (Burkitt), salted fish/NPC genetics, H. pylori (gastric), immunosuppression.
Clinical Presentation of Mono
- Fever, pharyngitis, cervical lymphadenopathy, fatigue.
- Splenomegaly (50%), hepatomegaly, periorbital edema.
- Atypical lymphocytosis (>10% atypical lymphocytes).
- Heterophile antibody (Monospot) positive; EBV VCA IgM confirms.
Prevention & Research
- No licensed vaccine yet. Several candidates in trials (gp350 subunit, nanoparticle, mRNA).
- Challenge: Lifelong latency; need to prevent initial infection OR block oncogenesis.
- Antivirals (acyclovir) reduce shedding but don't eradicate latency.
- EBV viral load monitoring guides PTLD preemptive therapy.
Key point: EBV infection is near-universal; cancer is rare. Most carriers never develop malignancy. Research focuses on identifying high-risk hosts and interception strategies.
Viral Infections - Related Articles
- Parvovirus in Dogs: Natural Home Remedies & Symptoms
- Fifth Disease in Adults: Symptoms, Risks & Complications
- Rabies in Mammals: Understanding Transmission and Why Other Animals Aren't Affected
- Viral Life Cycle: Five Steps from Entry to Release
- Meningitis & Septicemia: Understanding Risks, Symptoms & Treatment
- Rabies: Understanding the Virus Lifecycle and Transmission
- Shingles: Causes, Symptoms, Treatment & Prevention | [Your Brand Name]
